Exelixis reported $102.86M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US $ 96.68M 9.23M
Agios Pharmaceuticals AGIO:US $ 31.51M 13K
Akebia Therapeutics AKBA:US $ 44.33M 498K
Amgen AMGN:US $ 1.23B 197M
AstraZeneca AZN:LN 3.06B 1.03B
Bayer BAYN:GR 3.94B 346M
Biomarin Pharmaceutical BMRN:US $ 194.62M 22.94M
Bristol Myers Squibb BMY:US $ 1.83B 523M
Cytokinetics CYTK:US $ 33.07M 736K
Eisai 4523:JP 110.49B 9.03B
Eli Lilly And LLY:US $ 1.56B 34.1M
Esperion Therapeutics ESPR:US $ 30.38M 5.29M
Exelixis EXEL:US $ 102.86M 3.55M
Genmab GEN:DC 452M 60M
Glaxosmithkline GSK:US 2.68B 227M
Immunogen IMGN:US $ 16.65M 3.07M
Macrogenics MGNX:US $ 16.25M 670K
Merk MRK:US $ 2.3B 518M
Mirati Therapeutics MRTX:US $ 53.95M 10.42M
Moderna Inc MRNA:US 268M 67M
Nektar Therapeutics NKTR:US $ 27.34M 4.8M
Novartis NOVN:VX 3.5B 486M
Puma Biotechnology PBYI:US $ 20.4M 2.06M
Seattle Genetics SGEN:US $ 174.22M 36.71M
Takeda 4502:JP 223.43B 7.65B
Ultragenyx Pharmaceutical RARE:US $ 67.31M 7.88M
Xencor XNCR:US $ 11.27M 102K
YTE INCY:US $ 209.58M 16.62M